Everybody's different — and everyone's depression is different, too. If you and your doctor decide to try antidepressant medications to help treat your depression, you’ll work together to find one ...

Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of disability and low quality of life. One in every three people suffering from MDD ...

Major depressive disorder (MDD) is a severe form of depression characterized by a persistent low mood, hopelessness, ...

SNRIs have approval from the U.S. Food and Drug Administration (FDA) to treat the symptoms of depression, anxiety disorders, chronic nerve pain, and other health conditions. They do this by changing ...

Pfizer has announced positive topline results from a phase 4 efficacy study of the selective serotonin and norepinephrine reuptake inhibitor (SNRI) desvenlafaxine (Pristiq) extended-release tablets ...

SNRI use in late pregnancy was associated with an increased risk for hypertensive disorders compared with SSRIs (adjusted hazard ratio [aHR], 1.80; 95% CI, 1.37-2.35). Venlafaxine specifically showed ...

Desvenlafaxine, the major active metabolite of venlafaxine (Effexor XR, also from Wyeth), is a potent and selective SNRI. The increase in the effects of these neurotransmitters in the central nervous ...

Results showed that discontinuation of any SNRI was associated with withdrawal symptoms, with the highest prevalence linked to venlafaxine and desvenlafaxine. Serotonin-noradrenaline reuptake ...

Adding serotonin and norepinephrine reuptake inhibitors (SNRIs) to short-acting opioids for nonmalignant pain in nursing home residents doesn’t seem to boost their risk for delirium compared with ...